Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamster
A Kobayashi,
T Yamashita,
M Kaneko,
T Nishiyama,
H Hayashi,
and
N Yamazaki
Third Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka Prefecture, Japan.
The Bio 14.6 Syrian hamster provides a good model for experimental study of cardiomyopathy. Cardiac receptor binding sites (alpha-1-, beta- and calcium antagonists) were studied in early (21 days old) and late (70 days old) stages of cardiomyopathy. The effects of verapamil on histologic features and free radicals in the heart were studied. The number of alpha-1- and beta-cardiac receptor binding sites was significantly greater in the late stage of cardiomyopathy when compared with findings in normal golden hamsters used as controls. The calcium antagonist receptors were significantly increased in the early stage but alpha-1- and beta-receptors were not. Verapamil-treated hamsters received intraperitoneal injections of verapamil at a dose of 5 mg/kg per day for 70 days from age 20 days. The percent areas of fibrosis and calcification in the verapamil-treated group were significantly smaller than those in the control group. The concentrations of lipid peroxides in the whole heart and free radicals in the heart mitochondria were significantly higher in the cardiomyopathic hamsters, and verapamil inhibited the increase in free radical concentration in the hearts of these hamsters. This study confirms that the number of calcium channels is increased early in the course of cardiomyopathy in the Bio 14.6 Syrian hamster. A larger number of free radicals may participate in the accumulation of calcium and cell injury in the myocytes of these hamsters. Verapamil protects against myocardial damage and may do so by inhibiting voltage-dependent calcium uptake and by preventing cell injury from free radicals.
This article has been cited by other articles:
|
|
|
|
 
A. Stempien-Otero, A. Plawman, J. Meznarich, T. Dyamenahalli, G. Otsuka, and D. A. Dichek
Mechanisms of Cardiac Fibrosis Induced by Urokinase Plasminogen Activator
J. Biol. Chem.,
June 2, 2006;
281(22):
15345 - 15351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E Keith, K. N Jeejeebhoy, A. Langer, R. Kurian, A. Barr, B. O'Kelly, and M. J Sole
A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure
Am J Clin Nutr,
February 1, 2001;
73(2):
219 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Clark and L. C. Fuchs
BKCa channels compensate for loss of NOS-dependent coronary artery relaxation in cardiomyopathy
Am J Physiol Heart Circ Physiol,
December 1, 2000;
279(6):
H2598 - H2603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Inada, H. Fujiwara, K. Hasegawa, M. Araki, R. Yamauchi-Kohno, H. Yabana, T. Fujiwara, M. Tanaka, and S. Sasayama
Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters
J. Am. Coll. Cardiol.,
February 1, 1999;
33(2):
565 - 571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Ohkubo, H. Matsubara, Y. Nozawa, Y. Mori, S. Murasawa, K. Kijima, K. Maruyama, H. Masaki, Y. Tsutumi, Y. Shibazaki, et al.
Angiotensin Type 2 Receptors Are Reexpressed by Cardiac Fibroblasts From Failing Myopathic Hamster Hearts and Inhibit Cell Growth and Fibrillar Collagen Metabolism
Circulation,
December 2, 1997;
96(11):
3954 - 3962.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Dagenais, R. Cartier, C. Hollmann, and J. Buluran
Calcium-Channel Blockers Preserve Coronary Endothelial Reactivity After Ischemia-Reperfusion
Ann. Thorac. Surg.,
April 1, 1997;
63(4):
1050 - 1056.
[Abstract]
[Full Text]
|
|
|
|
